Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at Cowen
Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen in a research report issued to clients and investors on Tuesday, The Fly reports.
Separately, BTIG Research initiated coverage on shares of Y-mAbs Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 price objective on the stock.
Shares of NASDAQ:YMAB traded down $0.40 during midday trading on Tuesday, hitting $20.75. The stock had a trading volume of 1,250 shares, compared to its average volume of 161,224. Y-mAbs Therapeutics has a 1 year low of $20.00 and a 1 year high of $31.00.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.